Olufunmilayo Olopade to Middle Aged
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Middle Aged.
Connection Strength
2.804
-
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
Score: 0.060
-
Cancer Genetic Services in a Low- to Middle-Income Country: Cross-Sectional Survey Assessing Willingness to Undergo and Pay for Germline Genetic Testing. JCO Glob Oncol. 2023 02; 9:e2100140.
Score: 0.060
-
Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Glob Oncol. 2022 05; 8:e2200017.
Score: 0.056
-
Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
Score: 0.055
-
Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. BMC Complement Med Ther. 2020 Mar 20; 20(1):93.
Score: 0.049
-
Infrastructural Challenges Lead to Delay of Curative Radiotherapy in Nigeria. JCO Glob Oncol. 2020 02; 6:269-276.
Score: 0.048
-
Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. Int J Cancer. 2019 12 15; 145(12):3321-3333.
Score: 0.046
-
Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018 10; 17(4):495-505.
Score: 0.044
-
Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
Score: 0.044
-
Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018 10 01; 36(28):2820-2825.
Score: 0.044
-
Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. J Glob Oncol. 2018 07; 4:1-8.
Score: 0.043
-
Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns. 2018 12; 27(6):1405-1410.
Score: 0.043
-
Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. J Genet Couns. 2018 08; 27(4):863-873.
Score: 0.042
-
Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016 08 23; 7(34):55231-55248.
Score: 0.038
-
Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. 2015 Jul 01; 121(13):2237-43.
Score: 0.034
-
Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Glob Public Health. 2015; 10(3):331-44.
Score: 0.034
-
Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
Score: 0.034
-
Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
Score: 0.033
-
Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. Ann Diagn Pathol. 2013 Dec; 17(6):526-30.
Score: 0.031
-
Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J. 2013 Sep-Oct; 19(5):470-7.
Score: 0.031
-
Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013 May 10; 12(1):40.
Score: 0.030
-
Level of awareness of mammography among women attending outpatient clinics in a teaching hospital in Ibadan, South-West Nigeria. BMC Public Health. 2013 Jan 16; 13:40.
Score: 0.030
-
Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clin Breast Cancer. 2013 Apr; 13(2):156-8.
Score: 0.030
-
Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One. 2012; 7(7):e40494.
Score: 0.029
-
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
Score: 0.029
-
Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes Control. 2012 Apr; 23(4):565-74.
Score: 0.028
-
Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012 Apr; 33(4):835-40.
Score: 0.028
-
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
Score: 0.028
-
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
Score: 0.027
-
Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
Score: 0.027
-
Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 2011 Mar 01; 117(5):907-15.
Score: 0.025
-
Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010 Sep 15; 172(6):682-90.
Score: 0.025
-
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
Score: 0.025
-
Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat. 2010 Nov; 124(2):573-7.
Score: 0.025
-
Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast J. 2010 Jan-Feb; 16(1):110-2.
Score: 0.024
-
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
Score: 0.023
-
Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
Score: 0.023
-
Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
Score: 0.022
-
Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns. 2008 Aug; 17(4):365-72.
Score: 0.022
-
Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
Score: 0.021
-
Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008 Mar 11; 98(5):992-6.
Score: 0.021
-
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008 Sep; 111(1):113-20.
Score: 0.021
-
Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat. 2008 Jul; 110(2):367-76.
Score: 0.021
-
UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos. 2007 Aug; 35(8):1254-61.
Score: 0.020
-
Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns. 2006 Aug; 15(4):267-76.
Score: 0.019
-
BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006 Apr; 47(4):765-7.
Score: 0.019
-
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005 Dec 01; 65(23):10692-9.
Score: 0.018
-
Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
Score: 0.017
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
Score: 0.016
-
Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
Score: 0.016
-
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1547-1555.
Score: 0.016
-
Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol. 2003 Jul; 13(6):455-61.
Score: 0.015
-
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
Score: 0.015
-
Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
Score: 0.015
-
Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):98-104.
Score: 0.015
-
The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
Score: 0.015
-
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002 Mar 01; 62(5):1481-8.
Score: 0.014
-
Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2022 Feb; 29(2):1423-1432.
Score: 0.014
-
The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021 11 01; 127(21):4072-4080.
Score: 0.013
-
Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001 Mar; 38(3):159-64.
Score: 0.013
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
Score: 0.013
-
Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
Score: 0.013
-
A case of pulmonary toxicity associated with G-CSF and doxorubicin administration. Ann Hematol. 2001 Feb; 80(2):121-3.
Score: 0.013
-
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
Score: 0.013
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
Score: 0.013
-
Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000 Aug; 107(2):186-91.
Score: 0.013
-
Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet. 2000 Aug; 107(2):192-4.
Score: 0.013
-
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020 06 16; 10(1):9688.
Score: 0.012
-
Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer. 2000 Jun; 28(2):164-72.
Score: 0.012
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.012
-
Care Coordination for Breast Cancer Survivors in Urban Underserved Communities: Will Treatment Summaries and Survivorship Care Plans Be Enough? J Racial Ethn Health Disparities. 2020 06; 7(3):577-583.
Score: 0.012
-
Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
Score: 0.012
-
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
Score: 0.012
-
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
Score: 0.012
-
Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
Score: 0.012
-
N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians. Pharmacogenet Genomics. 2019 07; 29(5):106-113.
Score: 0.012
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
Score: 0.012
-
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Jun; 175(2):443-449.
Score: 0.011
-
Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 02; 120(4):398-403.
Score: 0.011
-
Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Res. 2019 01 14; 21(1):3.
Score: 0.011
-
Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet. 2019 02; 95(2):293-301.
Score: 0.011
-
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
Score: 0.011
-
Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst. 2018 09 01; 110(9):985-993.
Score: 0.011
-
Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
Score: 0.011
-
CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev. 2018 11; 27(11):1364-1370.
Score: 0.011
-
Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Mol Carcinog. 2018 10; 57(10):1311-1318.
Score: 0.011
-
Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 1998 May; 22(1):72-8.
Score: 0.011
-
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018 02 01; 110(2).
Score: 0.011
-
Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Res Treat. 2018 Apr; 168(3):703-712.
Score: 0.010
-
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
Score: 0.010
-
Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. Int J Cancer. 2018 01 01; 142(1):36-43.
Score: 0.010
-
Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 1997 Jul-Aug; 3(4):230-7.
Score: 0.010
-
Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
Score: 0.010
-
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
Score: 0.010
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
Score: 0.010
-
Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet. 1997 May; 60(5):1233-6.
Score: 0.010
-
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
Score: 0.010
-
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood. 1996 Sep 15; 88(6):2354-5.
Score: 0.010
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
Score: 0.009
-
Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet. 2016 10; 135(10):1145-59.
Score: 0.009
-
Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996 Apr; 10(4):669-74.
Score: 0.009
-
An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
Score: 0.009
-
Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
Score: 0.009
-
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
Score: 0.009
-
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
Score: 0.009
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
Score: 0.009
-
Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood. 1995 Sep 01; 86(5):1931-8.
Score: 0.009
-
Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
Score: 0.009
-
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
Score: 0.009
-
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
Score: 0.009
-
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
Score: 0.008
-
Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast. 2015 Apr; 24(2):131-6.
Score: 0.008
-
Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015 Apr 01; 121(7):1071-8.
Score: 0.008
-
National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol. 2014 Dec 20; 32(36):4095-101.
Score: 0.008
-
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
Score: 0.008
-
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res. 2014; 16(4):424.
Score: 0.008
-
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul; 146(2):421-7.
Score: 0.008
-
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
Score: 0.008
-
Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. AJR Am J Roentgenol. 2013 Nov; 201(5):1155-63.
Score: 0.008
-
Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72.
Score: 0.008
-
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
Score: 0.008
-
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
Score: 0.008
-
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
Score: 0.008
-
Relationship between household air pollution from biomass smoke exposure, and pulmonary dysfunction, oxidant-antioxidant imbalance and systemic inflammation in rural women and children in Nigeria. Glob J Health Sci. 2013 Mar 18; 5(4):28-38.
Score: 0.008
-
Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 2013 Jul; 34(7):1520-8.
Score: 0.007
-
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013 Feb; 138(1):273-9.
Score: 0.007
-
Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992 Dec 01; 80(11):2873-82.
Score: 0.007
-
Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
Score: 0.007
-
Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. J Digit Imaging. 2012 Oct; 25(5):591-8.
Score: 0.007
-
A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48.
Score: 0.007
-
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
Score: 0.007
-
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
Score: 0.007
-
Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):552-6.
Score: 0.007
-
When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
Score: 0.007
-
DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog. 2012 Oct; 51 Suppl 1:E83-93.
Score: 0.007
-
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
Score: 0.007
-
Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat. 2012 Feb; 132(1):341-5.
Score: 0.007
-
Clinical implications of ERß methylation on sporadic breast cancers in Chinese women. Med Oncol. 2012 Sep; 29(3):1569-75.
Score: 0.007
-
Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Med Oncol. 2012 Sep; 29(3):1543-53.
Score: 0.007
-
Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
Score: 0.007
-
Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer. 2012 Apr 15; 118(8):2096-105.
Score: 0.007
-
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
Score: 0.007
-
Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
Score: 0.007
-
Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
Score: 0.007
-
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1690-702.
Score: 0.007
-
A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. Hum Genet. 2011 Dec; 130(6):767-75.
Score: 0.007
-
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
Score: 0.007
-
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011 May; 127(1):287-96.
Score: 0.006
-
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
Score: 0.006
-
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.
Score: 0.006
-
Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
Score: 0.006
-
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.
Score: 0.006
-
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
Score: 0.006
-
Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
Score: 0.006
-
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
Score: 0.006
-
Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010 Jun; 176(6):2911-20.
Score: 0.006
-
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
Score: 0.006
-
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
Score: 0.006
-
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
Score: 0.006
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.005
-
Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat. 2009 Aug; 116(3):441-7.
Score: 0.005
-
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008 Jul 22; 99(2):371-4.
Score: 0.005
-
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008 Jun; 40(6):703-6.
Score: 0.005
-
Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet. 2008 Apr 15; 182(2):69-74.
Score: 0.005
-
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr; 82(4):937-48.
Score: 0.005
-
Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008 Apr; 123(3):247-55.
Score: 0.005
-
RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008 Jan 01; 68(1):22-5.
Score: 0.005
-
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
Score: 0.005
-
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
Score: 0.005
-
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200.
Score: 0.005
-
How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
Score: 0.005
-
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1416-21.
Score: 0.005
-
Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
Score: 0.005
-
Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
Score: 0.005
-
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec; 3(12):e486.
Score: 0.005
-
The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet. 2006 Aug; 169(1):33-8.
Score: 0.005
-
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
Score: 0.005
-
"Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006 Jul; 21(7):779-85.
Score: 0.005
-
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
Score: 0.005
-
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43.
Score: 0.005
-
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9.
Score: 0.005
-
High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
Score: 0.005
-
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20; 117(6):988-91.
Score: 0.005
-
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10.
Score: 0.004
-
Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
Score: 0.004
-
A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1534-8.
Score: 0.004
-
Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol. 2005 Feb 01; 23(4):685-93.
Score: 0.004
-
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
Score: 0.004
-
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15; 22(12):2328-35.
Score: 0.004
-
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15; 10(6):2029-34.
Score: 0.004
-
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
Score: 0.004
-
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
Score: 0.004
-
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
Score: 0.004
-
Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology. 2002 Nov; 225(2):519-26.
Score: 0.004
-
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22.
Score: 0.004
-
Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81.
Score: 0.003
-
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8.
Score: 0.003
-
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
Score: 0.003
-
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
Score: 0.003
-
Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apher. 1999; 14(4):171-6.
Score: 0.003
-
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
Score: 0.003
-
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20; 90(10):761-6.
Score: 0.003
-
CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. Br J Haematol. 1995 Dec; 91(4):865-70.
Score: 0.002
-
Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res. 1993 Mar 01; 53(5):1098-101.
Score: 0.002
-
Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer. 1992 Nov; 5(4):357-74.
Score: 0.002
-
Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
Score: 0.002